Pharmamar

pharmamar.jpg

Contact information

Pharmamar, SA
Paula Mata Maneiro
Avda. De los Reyes, 1 Pol. Ind. La Mina
Colmenar Viejo
Madrid
918466000
918466001
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
    • Therapeutic areas
      • Oncology
  • D. Services
    • Professional services
  • CRO / CMO / SMO

PharmaMar, founded in 1986, is a Spanish biopharmaceutical company and a pioneer in the research and development of marine-based oncology treatments. Its focus is on exploring the ocean in search of compounds with antitumor activity, turning the sea into a powerful technological platform for the discovery of new molecules. Consequently, it boasts the world´s largest collection of marine organisms, comprising over 400,000 specimens. 

PharmaMar´s distinctive value lies in its unique approach: researching marine invertebrates as potential sources of medicinal compounds. Through an innovative biotechnological program, the company conducts marine expeditions around the globe to identify and study potential antitumor drugs.

PharmaMar covers the entire drug development process, from the initial research phase through production, logistics, and commercialization, ensuring the medicines reach patients. In Spain, they are leaders in R&D investment relative to their sales and per employee.

Products and services

PharmaMar has 3 approved products for 4 indications:

  • Small cell lung cancer
  • Ovarian cancer
  • Soft tissue sarcoma
  • Multiple myeloma

Additionally, it has a broad portfolio of drug candidates and a robust oncology R&D program, with products at various stages of clinical development for several types of cancer.

Biotech Sanitaria

Drugs National Companies
Product / Service Type Therapeutic area Development phase
ZEPZELCA (Lurbinectedin) + Irinotecan/Topotecan Biodrugs/ Drugs Oncología P III
ZEPZELCA (lurbinectedin) + Irinotecan Biodrugs/ Drugs Oncología P II
ZEPZELCA (lurbinectedin) + IO Biodrugs/ Drugs Oncología P III
ZEPZELCA (lurbinectedin) + Atezolizumab Biodrugs/ Drugs Oncología P III
ZEPZELCA (lurbinectedin) + Atezolizumab Biodrugs/ Drugs Oncología P II
PM54 Biodrugs/ Drugs Oncología P I
PM534 Biodrugs/ Drugs Oncología P I
PM14 (ecubectedin) combination trials Biodrugs/ Drugs Oncología P I
PM14 (ecubectedin) Biodrugs/ Drugs Oncología P II
PM14 (ecubectedin) combination radiation Biodrugs/ Drugs Oncología P I
PM14 (ecubectedin) Biodrugs/ Drugs Oncología P I